Leuco-Plus Indications/Uses

Cancer Patients Receiving Myelosuppressive Chemotherapy: Filgrastim is indicated in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia and fever. A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy, and twice per week during Filgrastim therapy to avoid leukocytosis and to monitor the neutrophil count. Filgrastim therapy should be discontinued when the ANC ≥10,000/mm³ after the expected chemotherapy-induced nadir.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy: Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML.
Cancer Patients Receiving Bone Marrow Transplant: Filgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with non-myeloid malignancies undergoing myelo-ablative chemotherapy followed by marrow transplantation. It is recommended that blood cells and platelet counts be obtained at a minimum of 3 times per week following marrow infusion to monitor the recovery of marrow reconstitution.
Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy: Filgrastim is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment after myeloablative chemotherapy.
Patients with Severe Chronic Neutropenia: Filgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g. fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.
It is essential that serial cell blood counts with differential and platelet counts and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of Filgrastim therapy. The use of Filgrastim prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition causing the neutropenia.
Pediatric Use in Severe Chronic Neutropenia and Cancer: Filgrastim is indicated for the treatment of the conditions previously described in pediatric patients. The efficacy and safety of Filgrastim are similar for adults and infants.
Prophylaxis and Treatment of Neutropenia in Patients with HIV/AIDS: Filgrastim is indicated in patients with neutropenic episodes associated with viral replication (HIV) or opportunistic infections in HIV/AIDS patients receiving anti-retroviral treatment like prophylaxis and patients with neutropenia secondary to chemotherapy and/or radiotherapy for malignant disease associated with their base disease.